Dr Anthony Curtis

Title: Senior Lecturer in Organic and Medicinal Chemistry
Phone: 01782 733040
Email: a.d.m.curtis@keele.ac.uk
Location: Jack Ashley Building. Room 0.06
Role: ISTM Research theme: Therapeutics
Pharmaceutical Science Team Lead
Contacting me: Please email in the first instance
Tony Curtis

I began my career at Keele University in 1993 in the Department of Chemistry, now part of the School of Chemical and Physical Sciences.  I then joined the Department of Medicines Management in 2005 as Director of Studies (Pharmaceutical Science) and played a major role, alongside others, in the development of the School of Pharmacy and Keele MPharm programme.  My academic position is currently Senior Lecturer in Organic and Medicinal Chemistry and I hold administrative roles within the School and the University.  I was awarded the Keele University Excellence in Learning and Teaching award in 2008 and I was awarded the Institute of Science and Technology in Medicine Research Fellowship for 2015-2016.  I have acted as an external examiner for higher degrees across the various disciplines within Chemistry.  My research into synthetic chemistry and drug discovery is aligned with the Keele Nanopharmaceutics Research Group.  I am a Fellow of the Royal Society of Chemistry and a Chartered Chemist (FRSC CChem) and a member of a number of other learned societies, including the American Chemical Society, the Academy of Pharmaceutical Sciences and the United Kingdom and Ireland Controlled Release Society.

ISTM Research theme: Therapeutics

My research interests lie at the interface between the physical and life sciences with a focus on the synthesis of molecules with biological or medicinal significance.

As a member of the Keele Nanopharmaceutics Research Group with Dr Clare Hoskins my research is directed towards the synthesis of drugs and delivery systems for the treatment of pancreatic cancer, the fourth most prevalent cancer in the Western World: Surgical intervention is currently the only treatment for pancreatic cancer with a survival rate 5 years following surgery of 5-34%. The only clinically-available chemotherapy for pancreatic cancer is gemcitabine which proves effective in 23.8% of patients, hence there is obvious interest in increasing the efficacy of gemcitabine and the discovery of novel therapeutic opportunities. My research interests in this area include the synthesis of novel chemotherapeutic agents and prodrugs for delivery to cancerous cells using gold-iron oxide hybrid nanoparticles HNPs) and the use of calixarenes for drug formulation and delivery.

Please click here for a link to the Keele Nanopharmaceutics Research Group website

I also collaborate with Dr Alan Richardson from the Keele School of Pharmacy in the synthesis of novel and adjunct therapies for the treatment of ovarian cancer (with Dr Jóhannes Reynisson, University of Auckland), and with Dr Paul Horrocks from the Keele School of Medicine in the development of drug-like molecules for use as antimalarial agents (with Dr Ravi Pathak, University of Cambridge).

Selected Publications

  • Oluwasanmi A, Al Shakarchi W, Manzur A, Aldebasi M, Elsini R, Albusair M, Haxton K, Curtis ADM, Hoskins C. 2017. Diels Alder-mediated release of gemcitabine from hybrid nanoparticles for enhanced pancreatic cancer therapy. Journal of Controlled Release, vol. 266, 355-364. doi> link>
  • Manzur A, Oluwasanmi A, Moss D, Curtis A, Hoskins C. 2017. Nanotechnologies in Pancreatic Cancer Therapy. Pharmaceutics, vol. 9(4). link> doi>
  • Oluwasanmi A, Al-Shakarchi W, Manzur A, Aldebasi MH, Elsini RS, Albusair MK, Haxton KJ, Curtis ADM, Hoskins C. 2017. Diels Alder-mediated release of gemcitabine from hybrid nanoparticles for enhanced pancreatic cancer therapy. J Control Release, vol. 266, 355-364. link> doi>
  • Malekigorji M, Alfahad M, Kong Thoo Lin P, Jones S, Curtis A, Hoskins C. 2017. Thermally triggered theranostics for pancreatic cancer therapy. Nanoscale, vol. 9(34), 12735-12745. link> doi>
  • Khare V, Al Sakarchi W, Gupta PN, Curtis ADM, Hoskins C. 2017. Further correction: Synthesis and characterization of TPGS-gemcitabine prodrug micelles for pancreatic cancer therapy (vol 6, 60126, 2016). RSC ADVANCES, vol. 7(28), 17367. link> doi>

Full Publications List show

Books

  • Curtis ADM and JENNINGS N. KATRITZKY AR, RAMSDEN CA, SCRIVEN EFV, TAYLOR RJK (Eds.). 2008. 1,2,4-Triazoles. (vol. 5). Oxford: Elsevier Ltd.
  • Curtis ADM. BELLUS D, LEY SV, NOYORI R, REGITZ M, REIDER PJ, SCHAUMANN E, SHINKAI I, THOMAS EJ, TROST BM (Eds.). 2003. 1,2,4-Triazoles. (vol. 13). Stuttgart: Georg Thieme Verlag.
  • Curtis ADM. REHM HJ, REED G, PUHLER A, STADLER P (Eds.). 2000. The Use of Enzymes in C-C Bond Formation. (vol. 8b). Stuttgart: VCH.
  • Curtis ADM. Katritzky AR, Rees CW, SCRIVEN EFV (Eds.). 1996. Bicyclic 5-5 Systems: Four Heteroatoms 1:3. (vol. 7). Oxford: Elsevier Science Ltd.
  • Curtis ADM. Katritzky AR, REES CW, SCRIVEN EFV (Eds.). 1996. Bicyclic 6-6 Systems: Four Heteroatoms 1:3. (vol. 7). Oxford: Elsevier Science Ltd.

Journal Articles

  • Oluwasanmi A, Al Shakarchi W, Manzur A, Aldebasi M, Elsini R, Albusair M, Haxton K, Curtis ADM, Hoskins C. 2017. Diels Alder-mediated release of gemcitabine from hybrid nanoparticles for enhanced pancreatic cancer therapy. Journal of Controlled Release, vol. 266, 355-364. doi> link>
  • Manzur A, Oluwasanmi A, Moss D, Curtis A, Hoskins C. 2017. Nanotechnologies in Pancreatic Cancer Therapy. Pharmaceutics, vol. 9(4). link> doi>
  • Oluwasanmi A, Al-Shakarchi W, Manzur A, Aldebasi MH, Elsini RS, Albusair MK, Haxton KJ, Curtis ADM, Hoskins C. 2017. Diels Alder-mediated release of gemcitabine from hybrid nanoparticles for enhanced pancreatic cancer therapy. J Control Release, vol. 266, 355-364. link> doi>
  • Malekigorji M, Alfahad M, Kong Thoo Lin P, Jones S, Curtis A, Hoskins C. 2017. Thermally triggered theranostics for pancreatic cancer therapy. Nanoscale, vol. 9(34), 12735-12745. link> doi>
  • Khare V, Al Sakarchi W, Gupta PN, Curtis ADM, Hoskins C. 2017. Further correction: Synthesis and characterization of TPGS-gemcitabine prodrug micelles for pancreatic cancer therapy (vol 6, 60126, 2016). RSC ADVANCES, vol. 7(28), 17367. link> doi>
  • Khare V, Al Sakarchi W, Gupta PN, Curtis ADM, Hoskins C. 2017. Synthesis and characterization of TPGS-gemcitabine prodrug micelles for pancreatic cancer therapy (vol 6, pg 60126, 2016). RSC ADVANCES, vol. 7(21), 12598. link> doi>
  • Oluwasanmi A, Malekigorji M, Jones S, Curtis A, Hoskins C. 2016. Potential of hybrid iron oxide-gold nanoparticles as thermal triggers for pancreatic cancer therapy. RSC ADVANCES, vol. 6(97), 95044-95054. link> doi>
  • Khare V, Al Sakarchi W, Gupta PN, Curtis ADM, Hoskins C. 2016. Synthesis and characterization of TPGS-gemcitabine prodrug micelles for pancreatic cancer therapy. RSC ADVANCES, vol. 6(65), 60126-60137. link> doi>
  • Hoskins C, Papachristou A, Ho TMH, Hine J, Curtis ADM. 2016. Investigation into drug solubilisation potential of sulfonated calix[4]resorcinarenes. Journal of Nanomedicine and Nanotechnology, vol. 7, Article 2. doi>
  • Curtis ADM, Malekigorji M, Holman J, Skidmore M, Hoskins C. 2015. Heat Dissipation of Hybrid Iron Oxide-Gold Nanoparticles in an Agar Phantom. Journal of Nanomedicine and Nanotechnology. doi>
  • Hoskins C and Curtis ADM. 2015. Simple Calixarenes and Resorcinarenes as Drug Solubilizing Agents. Journal of Nanomedicine Research, vol. 2(3), Article 28. doi>
  • Malekigorji M, Hoskins C, Curtis ADM, Varbiro G. 2014. Enhancement of the Cytotoxic Effect of Anticancer Agent by Cytochrome C Functionalised Hybrid Nanoparticles in Hepatocellular Cancer Cells. Journal of Nanomedicine Research, vol. 2(1), Article 10. doi>
  • Malekigorji M, Curtis ADM, Hoskins C. 2014. The Use of Iron Oxide Nanoparticles for Pancreatic Cancer Therapy. Journal of Nanomedicine Research, vol. 1(1), 1-12. doi>
  • Richardson A, Curtis ADM, Moss GP, Pearson RJ, White S, Rutten FJM, Perumal D, Maddock K. 2014. Simulated drug discovery process to conduct a synoptic assessment of pharmacy students. Am J Pharm Educ, vol. 78(2), 41. link> doi>
  • Barnett C, Lees M, Curtis ADM, Kong Thoo Lin P, Cheng WP, Hoskins C. Poly(allylamine) Magnetomicelles for Image Guided Drug Delivery. Pharmaceutical Nanotechnology, vol. 1(3), 224-238. doi>
  • Robinson E, Nandi M, Wilkinson L, Arrowsmith M, Curtis ADM, Richardson A. 2013. Preclinical Evaluation of Statins as a Treatment for Ovarian Cancer. Gynecologic Oncology, vol. 129, 417-424. doi>
  • Robinson E, Nandi M, Wilkinson LL, Arrowsmith DM, Curtis ADM, Richardson A. 2013. Preclinical evaluation of statins as a treatment for ovarian cancer. Gynecol Oncol, vol. 129(2), 417-424. link> doi>
  • Foley S, Curtis ADM, Hirsch A, Brettreich M, Pelegrin A, Seta P, Larroque C. 2002. Interaction of a water soluble fullerene derivative with reactive oxygen species and model enzymatic systems. FULLERENES NANOTUBES AND CARBON NANOSTRUCTURES, vol. 10(1), 49-67. link> doi>
  • Clews J, Curtis ADM, Malkin H. 2001. The synthesis of C-2-symmetric and axially chiral compounds for recognition and catalysis (vol 56, pg 8735, 2000). TETRAHEDRON, vol. 57(28), 6097. link> doi>
  • Clews J, Curtis ADM, Malkin H. 2000. The synthesis of C-2-symmetric and axially chiral compounds for recognition and catalysis. TETRAHEDRON, vol. 56(44), 8735-8746. link> doi>
  • Curtis ADM, Humphries MJ, Ramsden CA. 2000. Studies Directed Towards Conformationally Restricted Nucleosides. ARKIVOC, vol. 1(3), 218-227.
  • Curtis ADM, McCague R, Ramsden CA, Raza RR. 1999. Preparation, characterisation and slow quantitative dissociation of a novel asymmetric N-unsubstituted dialkylsulfimide. CHEMICAL COMMUNICATIONS, 189-190. link> doi>
  • Curtis ADM. 1997. Novel calix[4]resorcinarene glycosides. TETRAHEDRON LETTERS, vol. 38(24), 4295-4296. link> doi>
  • Cousins RPC, Curtis ADM, Ding WC, Stoodley RJ. 1995. 1,5-Asymmetric Inductions in the Reactions of 2-(2',3',4',6'-Tetra-O-acetyl-beta-D-glucopyranosyloxy)benzaldehyde with Danishefsky's Diene. Tetrahedron Letters, vol. 36(47), 8689-8692. doi>
  • Kelly TR, Kim MH, Curtis ADM. 1993. Structure Correction and Synthesis of the Naturally Occurring Benzothiazinone BMY 40662. Journal of Organic Chemistry, vol. 58(21), 5855-5857. doi>
  • Curtis ADM, Mears RJ, Whiting A. 1993. The Origin of the Stereoselectivity in the Aldol Reactions of beta-Boronate Carbonyl Derivatives. Tetrahedron, vol. 49(1), 187-198. doi>
  • Beagley B, Curtis ADM, Pritchard RG, Stoodley RJ. 1992. Asymmetric Diels-Alder Reactions. Part 6. Regio- and Stereo-selective Cycloadditions of 5-(2',3',4',6'-Tetra-O-acetyl-beta-D-glucopyranosyloxy)-1,4-naphthoquinone. Journal of the Chemical Society; Perkin Transactions 1, 1981-1991. doi>
  • Beagley B, Curtis ADM, Pritchard RG, Stoodley RJ. 1991. Highly Regio- and Stereo-selective Diel-Alder Reactions of 5-(2',3',4',6'-Tetra-O-acetyl-beta-D-glucopyranosyloxy)-1,4-naphthoquinone. Chemical Communications, 119-121. doi>
  • Curtis ADM and Whiting A. 1991. Stereoselective Aldol Reactions of beta-Boronate Carbonyl Derivatives. Tetrahedron Letters, vol. 32(11), 1507-1510. doi>

Chapters

  • Curtis ADM and Hoskins C. 2015. Potential Use of Hybrid Iron Oxide-Gold as Drug Carriers. In Nano Based Drug Delivery. IAPC-OBC. doi>
  • Hoskins C and Curtis ADM. 2015. Potential Use of Hybrid Iron Oxide-Gold as Drug Carriers. In Nano Based Drug Deliver. IAPC-OBC.
  • Curtis ADM and Jennings N. 2008. 1,2,4-Triazoles. In Comprehensive Heterocyclic Chemistry III: Five-membered rings: Triazoles, Oxadiazoles, Thiadiazoles and their Fused Carbocyclic Derivatives. KATRITZKY AR, RAMSDEN CA, SCRIVEN EFV, TAYLOR RJK (Eds.). (vol. 5.02). Oxford: Elsevier Ltd.
  • Curtis ADM. 2003. 1,2,4-Triazoles. In Science of Synthesis: 5-Membered Hetarenes with Three or More Heteroatoms. BELLUS D, LEY SV, NOYORI R, REGITZ M, REIDER PJ, SCHAUMANN E, SHINKAI I, THOMAS EJ, TROST BM (Eds.). (vol. 13). Stuttgart: Georg Thieme Verlag.
  • Curtis ADM. 2000. Carbon-Carbon Bond Formation, Addition, Elimination and Substitution Reactions: 1 Carbon-Carbon Bond Formation Using Enzymes. In Biotechnology: Biotransformations II. (vol. 8b). Stuttgart: VCH Verlag.
  • Curtis ADM. 1996. Bicyclic 5-5 Systems: Four Heteroatoms 1:3. In Comprehensive Heterocyclic Chemistry II: Fused Five and Six-membered Rings without Ring Junction Heteroatoms. KATRITZKY AR, REES CW, SCRIVEN EFV (Eds.). (vol. 7). Oxford: Elsevier Science Ltd.
  • Curtis ADM. 1996. Bicyclic 6-6 Systems: Four Heteroatoms 1:3. In Comprehensive Heterocyclic Chemistry II: Fused Five and Six-membered Rings without Ring Junction Heteroatoms. KATRITZKY AR, REES CW, SCRIVEN EFV (Eds.). (vol. 7). Oxford: Elsevier Science Ltd.

Other

  • Malekigorji M, Kong Thoo Lin P, Lees M, Gueorguieva M, Curtis A, Hoskins C. 2016. 587 - Thermally triggered theranostics for pancreatic cancer. European journal of cancer (vol. 61, p. S129). Elsevier. doi>
  • Curtis ADM. 2010. From Classroom To VLE And Back Again: A Blended Approach To Skills Development For Chemistry Students.
  • Malekigorji M, Curtis ADM, Hoskins C, Varbiro G. Hybrid Iron Oxide-Gold Nanoparticles as Drug Delivery Vehicles for Cancer Therapy.
  • Alfahad MAM, Hoskins C, Curtis A. LOADING AND RELEASE OF NOVAL GEMCITABINE ADDUCT ONTO HYBRID GOLD IRON-OXIDE NANOPARTILCE FOR PANCREATIC CANCER THERAPY.
  • Oluwasanmi A, Curtis A, Hoskins C. Novel Iron Oxide-Gold Nanohybrids with Heat Triggered Surface Manipulation.
  • Oluwasamni A, Curtis ADM, Hoskins C. Novel Iron Oxide-Gold Nanohybrids with Heat Triggered Surface Manipulation.
  • Oluwasanmi A, Curtis ADM, Hoskins C. Novel Iron Oxide-Gold Nanohybrids with Heat-Triggered Surface Manipulation.
  • Barnett C, Cheng WP, Lees M, Curtis ADM, Kong Thoo Lin P, Hoskins C. Poly(allylamine) Magnetomicelles for Image Guided Drug Delivery.
  • Barnett C, Lees M, Curtis ADM, Kong Thoo Lin P, Cheng WP, Hoskins C. Poly(allylamine) Magnetomicelles for Image Guided Drug Delivery.
  • Alfahad M, Hoskins C, Curtis A. Synthesis of novel hybrid nanoparticle-prodrug constructs for pancreatic cancer therapy.
  • Alfahad M, Hoskins C, Curtis A. Synthesis of novel hybrid nanoparticulate-prodrug constructs for pancreatic cancer therapy.
  • Alfahad MAM, Hoskins C, Curtis ADM. Synthesis of Novel Hybrid Nanoparticulate-Prodrug Constructs for Pancreatic Cancer Therapy.
  • Alfahad MAM, Hoskins C, Curtis ADM. Synthesis of Novel Hybrid Nanoparticulate-Prodrug Constructs for Pancreatic Cancer Therapy.
  • Malekigorji M, Kong Thoo Lin P, Lees M, Gueorguieva M, Curtis A, Hoskins C. Temperature controlled theranostics for pancreatic cancer.
  • Malekigorji M, Kong Thoo Lin P, Lees M, Gueorguieva M, Curtis A, Hoskins C. TEMPERATURE CONTROLLED THERANOSTICS FOR PANCREATIC CANCER.
  • Al Shakarchi W, Varbiro G, Curtis A, Hoskins C. The co-administration of anticancer and pro-apoptotic agents as novel approach in liver cancer therapy.
  • Alsuraifi A, Curtis A, Hoskins C. Thermoresponsive copolymer: (HPMA-CO-(APMA-R))-co-PEG polymer synthesis and physiochemical characterization.
  • Alsuraifi A, Curtis A, Hoskins C. Thermoresponsive copolymer: HPMA-co-AMPA-R polymer synthesis and physiochemical characterization.

I welcome applications from students who wish to undertake PhD postgraduate studies in my team. Former, and current, postgraduate students include UK nationals as well as overseas students from the Middle East and India, undertaking full-time studies in my laboratory. Interested students can contact me directly on a.d.m.curtis@keele.ac.uk to discuss potential projects as well as the application process for these degrees.

My current research interests are in Nanopharmaceutics. Nanopharmaceutics is a form of nanotechnology that involves the formulation of medicines into very small dosage forms suitable for administration by various routes as required, intravenously for example (nanomedicine). Often drug molecules have undesirable properties: For example, drugs may not be very soluble in water or they may not be absorbed well by the body which hinders their usage. These drugs require careful formulation in order for them to be administered to patients effectively and display their proposed therapeutic effect. Traditional formulation strategies do not live up to the high demand in recent years where approximately 60% of all new drugs under development are classed as practically insoluble in water, hence the increase in nanomedicine research worldwide. The most common nano-systems for drug formulation are core-shell based systems. Many of these systems have undergone the rigors of regulatory testing and are now licensed for use in the clinic across the globe.

The nano-structures act as chaperones for the drug molecules, carrying their cargo past the body’s defense systems to their intended target site, thus avoiding any premature drug degradation or metabolism. The nano-carriers themselves are relatively simple and cheap to make and they can be easily tailored for application. This tailoring may include inclusion of specific functional groups which help the particle reach their destination more easily or confer additional properties, such as fluorescence in order for their journey after administration to be tracked.

Nanopharmaceutics research has experienced exponential growth internationally in the past ten years. Here in ISTM we have a highly motivated and interdisciplinary Nanopharmaceutics team who strive to drive forward innovation in this area. Our area of research spans across the boundaries of chemistry, physics and the life sciences with an aim to produce novel nanomedicines for a wide variety of different diseases with a special focus on pancreatic cancer. For more information please have a look at the Nanopharmaceutics research group website:

https://www.keele.ac.uk/pharmacy/research/nanopharmaceutics/

Or contact me directly.